Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported. such as pneumonitis. hepatitis. https://www.roneverhart.com/Tasoliesi-Hackman-RTL-6-levyinen-15kW/